Emalex Bioscience News Today

/PRNewswire/ -- DelveInsights Stuttering Market Insights report includes a comprehensive understanding of current treatment practices, stuttering emerging...

The anticipated introduction of new therapeutic options could lead to an expansion of the market for stuttering treatment during the forecast period. This growth may be fueled by factors such

Emalex Biosciences will use the cash from its Series D financing to conduct a Phase 3 clinical trial for ecopipam, an experimental treatment for Tourette syndrome. Though there drugs are already available for Tourette, Emalex’s drug addresses a different central nervous system target that the biotech believes could offer an edge.